National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 22498 [2018-10316]

Download as PDF daltland on DSKBBV9HB2PROD with NOTICES 22498 Federal Register / Vol. 83, No. 94 / Tuesday, May 15, 2018 / Notices ORI found that Respondent engaged in research misconduct by knowingly and intentionally falsifying data reported in Development 141(12):2414– 28, 2014 Jun (hereafter referred to as ‘‘Development 2014’’). In addition to making an admission, Respondent cooperated fully with ISMMS and ORI and has expressed remorse for his actions. Specifically, ORI found that Respondent: • used the p-GSK3a/b double bands in Figure S3B of Development 2014, removed the lower set of bands, reordered the remaining bands and used those bands to represent the actin control in an experiment comparing the impact of Tgfb1 and ActB individually and in combination in primary oligodendrocyte progenitors (OLPs) and the oligodendrocyte-derived Oli-Neu cell line. • used the densitometry readings from the falsified actin bands in Figure S3B of Development 2014 to compare the density of A+T, Tgfb1, ActB, and Veh relative to the false actin signal in Figure S3C–J, creating eight false graphs. • falsified the bands representing Myelin basic protein (Mbp) in Figure 3C of Development 2014 by cutting and pasting the bands onto a blank background and used those false bands to create a graph showing the density of Mbp in the presence and absence of ActB, Tgfb1, and Bmp4. As a result of this admission, Respondent has notified Development that corrections to figures in the paper, but not to the text, including the conclusions in Development 2014 are required. Dr. John entered into a Voluntary Settlement Agreement and voluntarily agreed, beginning on April 26, 2018: (1) To have his research supervised for a period of one (1) year; Respondent agreed that prior to submission of an application for U.S. Public Health Service (PHS) support for a research project on which the Respondent’s participation is proposed and prior to Respondent’s participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondent’s duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of Respondent’s research contribution; Respondent agreed that he shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; VerDate Sep<11>2014 20:27 May 14, 2018 Jkt 244001 (2) that for one (1) year, any institution employing him shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; (3) if no supervisory plan is provided to ORI, to provide certification to ORI at the conclusion of the supervision period that he has not engaged in, applied for, or had his name included on any application, proposal, or other request for PHS funds without prior notification to ORI; (4) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of one (1) year; and (5) to follow up with the journal editor regarding his previous request to correct the following paper to ensure that the corrections are made: • Development 141(12):2414–28, 2014 Jun. Wanda K. Jones, Interim Director, Office of Research Integrity. [FR Doc. 2018–10310 Filed 5–14–18; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of Microbiology, Infectious Diseases and AIDS Initial Review Group Microbiology and Infectious Diseases Research Committee. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 Name of Committee: Microbiology, Infectious Diseases and AIDS Initial Review Group Microbiology and Infectious Diseases Research Committee. Date: June 7–8, 2018. Time: 9:30 a.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Frank S. De Silva, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3E72A, National Institutes of Health/ NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892934, (240) 669–5023, fdesilva@niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: May 10, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–10316 Filed 5–14–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the meeting of the National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; P41 BTRC Review (2018/10). Date: July 5–7, 2018. Time: 6:00 p.m. to 1:00 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: Courtyard by Marriott New York Manhattan/Upper ES, 410 East 92nd Street, New York, NY 10128. Contact Person: Manana Sukhareva, Ph.D., Scientific Review Officer, National Institute E:\FR\FM\15MYN1.SGM 15MYN1

Agencies

[Federal Register Volume 83, Number 94 (Tuesday, May 15, 2018)]
[Notices]
[Page 22498]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-10316]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of Microbiology, 
Infectious Diseases and AIDS Initial Review Group Microbiology and 
Infectious Diseases Research Committee.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Microbiology, Infectious Diseases and AIDS 
Initial Review Group Microbiology and Infectious Diseases Research 
Committee.
    Date: June 7-8, 2018.
    Time: 9:30 a.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 5601 Fishers Lane, 
Rockville, MD 20892 (Telephone Conference Call).
    Contact Person: Frank S. De Silva, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, Room #3E72A, National Institutes of Health/NIAID, 5601 
Fishers Lane, MSC 9834, Bethesda, MD 20892934, (240) 669-5023, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: May 10, 2018.
Natasha M. Copeland,
 Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-10316 Filed 5-14-18; 8:45 am]
BILLING CODE 4140-01-P